Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.”In the company’s words, NCT06000956 on ClinicalTrials.gov
- Tested for
- Ankylosing Spondylitis
- Main trialPhase 3
- “The goal of this clinical trial is evaluating the efficacy and safety of Jitongning tablets in participant population. The main questions it aims to answer are: * Based on the proportion of participants who achieved improvement in ASAS20, evaluate whether the efficacy of Jitongning tablets is superior to placebo in active ax-SpA adult participants. * Evaluate the efficacy of Jitongning tablets in improving other key functions and symptom outcomes. * Evaluating the safety of Jitongning tablets in adult ax-SpA participants. Participants will 1. take orally Jitongning tablets or a simulated…”In the company’s words, NCT06000956 on ClinicalTrials.gov
- Other names
- 3tablets
Other drugs for Ankylosing Spondylitis
- LNK01001Lynk Pharmaceuticals Co., Ltd · Phase 3
- 6083SBio · Phase 3
- HS_SW01 cellsShenzhen Huishan Biotechnology Co., Ltd. · Phase 1/2
- VilamakitugXBiotech, Inc. · Phase 2
- HB0017Huahai Pharmaceutical (Huaota) · Phase 1
- Human Umbilical Cord Mesenchymal Stem CellsAsia Cell Therapeutics (Shanghai) Co., Ltd. · Phase 1
Coming up1
- 1 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Dec 2026 | A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo | |
| Phase 2Completed | 20 Jun 2021 | Study of Jitongning Tablet to Treat Spondyloarthritis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026